{
  "event": {
    "ticker": "MLYS",
    "company": "Mineralys Therapeutics, Inc.",
    "drug": "lorundrostat",
    "application_type": "NDA",
    "indication": "Hypertension in adults, in combination with other antihypertensive drugs (uncontrolled or resistant hypertension)",
    "pdufa_date": "2026-12-22"
  },
  "display": {
    "company": "Mineralys",
    "drug": "lorundrostat",
    "indication_en": "Uncontrolled or resistant hypertension",
    "indication_zh": "未控制或难治性高血压"
  },
  "probability_approval": 0.88,
  "confidence": "medium",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "FDA approved the first drug of this class in May 2026 for almost the same indication",
      "direction": "+",
      "step": "large",
      "evidence": "On 15 May 2026 FDA approved AstraZeneca's Baxfendy (baxdrostat), the first aldosterone synthase inhibitor, for \"the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents\". Lorundrostat's application seeks \"the treatment of adult patients with hypertension in combination with other antihypertensive drugs\". The baxdrostat approval rested on blood-pressure lowering in one phase 3 trial (BaxHTN, 794 patients randomized): seated systolic pressure at week 12 fell 9.8 mmHg (2 mg) and 8.7 mmHg (1 mg) more than on placebo, both p<0.0001. The label states that no controlled trial shows fewer cardiovascular events with the drug itself. It has no boxed warning and no contraindications; hyperkalemia and hyponatremia are warnings managed by blood tests. The approval letter says the application was not referred to an advisory committee because it \"did not raise significant public health questions\" and there were \"no controversial issues\"; the studies it requires after approval cover only children, lactation and pregnancy. The letter was signed by the director of FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, whose remit includes hypertension drugs. Limits of the precedent: baxdrostat came from a large company under priority review, and its approval says nothing about how lorundrostat is manufactured.",
      "source": "FDA approval letter, NDA 219878, signed 2026-05-15: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf; Baxfendy prescribing information, revised 5/2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf; Mineralys 8-K, 2026-03-09: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm; HCPLive, 2025-12-02 (priority review): https://www.hcplive.com/view/fda-accepts-priority-review-nda-of-baxdrostat-for-uncontrolled-hypertension"
    },
    {
      "factor": "Both pivotal trials met their primary endpoints clearly",
      "direction": "+",
      "step": "medium",
      "evidence": "Launch-HTN (phase 3; 1,083 adults taking 2 to 5 blood-pressure medicines, 159 sites in 13 countries; JAMA 2025): at week 6, automated office systolic pressure fell 16.9 mmHg on lorundrostat 50 mg and 7.9 mmHg on placebo, a difference of 9.1 mmHg (95% CI 4.9 to 13.3; P<.001). At week 12 the difference was 11.6 mmHg for 50 mg (p<0.0001) and 8.4 mmHg for the arm allowed to increase to 100 mg (p=0.0016). Advance-HTN (phase 2, designated pivotal; 285 adults still hypertensive on a standardized regimen; NEJM 2025): 24-hour ambulatory systolic pressure at week 12 fell 7.9 mmHg more than on placebo with 50 mg (97.5% CI 2.6 to 13.3) and 6.5 mmHg more in the dose-adjustment arm (97.5% CI 1.2 to 11.8). Supporting trials point the same way: Target-HTN (200 patients; 9.6 mmHg for 50 mg, P=.01) and Explore-CKD (59 patients with kidney disease; 7.5 mmHg with 25 mg, p=0.0024). Explore-OSA missed its primary endpoint, a sleep-apnea measure that is not part of this application; blood pressure still fell 6.2 mmHg more than on placebo. These effects are in the same range as baxdrostat's. The 100 mg dose added nothing over 50 mg; the company has said it is seeking 25 mg and 50 mg.",
      "source": "Launch-HTN, JAMA 2025;334:409-418: https://pubmed.ncbi.nlm.nih.gov/40587141/; Advance-HTN, N Engl J Med 2025;392:1813-1823: https://pubmed.ncbi.nlm.nih.gov/40267417/; Target-HTN, JAMA 2023;330:1140-1150: https://pubmed.ncbi.nlm.nih.gov/37690061/; Explore-CKD, Kidney Int 2026: https://pubmed.ncbi.nlm.nih.gov/42778148/; Mineralys 10-K filed 2026-03-12: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm; Mineralys 8-K, 2026-03-09 (Explore-OSA): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm; Investing.com report of the Wells Fargo conference, 2026-09-09 (doses sought): https://in.investing.com/news/stock-market-news/mineralys-at-wells-fargo-conference-lorundrostat-launch-takes-shape-93CH-5587269"
    },
    {
      "factor": "No cortisol suppression, and a safety database at least as large as the one described in the first approval's label",
      "direction": "+",
      "step": "small",
      "evidence": "The long-standing worry with this class is that it also blocks cortisol production. In Launch-HTN no participant on lorundrostat had glucocorticoid deficiency confirmed by stimulation testing, and Target-HTN reported no cortisol insufficiency; Baxfendy's label likewise reports no effect on stimulated cortisol. In Launch-HTN serious adverse events were less frequent on lorundrostat (2.2% and 0.7%) than on placebo (3.0%), and the only death was in the placebo arm. The two pivotal trials randomized 1,001 patients to lorundrostat (811 + 190), and 1,076 patients entered the Transform-HTN extension study, which offers up to 52 weeks of open-label treatment, includes a randomized withdrawal phase and supported the application. For comparison, Baxfendy's label describes 12-week controlled data from 774 treated patients and long-term data from 192 and 172 patients. How many lorundrostat patients in the application were treated for a year or more has not been published; long-term results are due at the American Heart Association meeting on 8 November 2026.",
      "source": "Launch-HTN, JAMA 2025 (full text, Table 3): https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/; Target-HTN, JAMA 2023: https://pubmed.ncbi.nlm.nih.gov/37690061/; Advance-HTN, N Engl J Med 2025: https://pubmed.ncbi.nlm.nih.gov/40267417/; Mineralys 10-K filed 2026-03-12: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm; ClinicalTrials.gov NCT05968430 (Transform-HTN): https://clinicaltrials.gov/study/NCT05968430; Baxfendy prescribing information, sections 6.1 and 12.2: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf; Mineralys press release, 2026-09-23: https://ir.mineralystx.com/news-events/press-releases/detail/116/mineralys-therapeutics-transform-htn-open-label"
    },
    {
      "factor": "Potassium, sodium and kidney-function effects, more marked in the higher-risk trial",
      "direction": "-",
      "step": "small",
      "evidence": "Lorundrostat raises potassium, lowers sodium and reduces measured kidney function more often than placebo. In Launch-HTN the published adverse events of special interest were hyperkalemia in 2.0% and 2.6% of the lorundrostat arms against 0.4% on placebo, hyponatremia in 6.9% and 10.4% against 3.3%, and reduced kidney function in 3.0% and 3.3% against 0.7%; fewer than 1% stopped treatment for any one of these. Potassium above 6.0 mmol/L was measured in 1.1% and 1.5% (0.6% and 1.1% after repeat testing). In Advance-HTN, where every patient was on an optimized regimen that included a diuretic and an angiotensin receptor blocker, potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the lorundrostat arms and in no one on placebo (2.1% and 3.2% after repeat testing), and serious adverse events were more frequent (6.4% and 8.4% against 2.1%); one death in the dose-adjustment arm was judged unrelated to the drug. In Explore-CKD confirmed hyperkalemia occurred in 3 of 58 patients (5%) on 25 mg and in none on placebo. Published pooled analyses of the same trials put the relative risk of hyperkalemia between 3.19 and 11.63. FDA dealt with the same effects for baxdrostat through warnings and monitoring, so these findings are more likely to shape the label than to block approval. Open points are how FDA counts potassium readings that were not confirmed on repeat testing, and whether the 25 mg dose, studied mainly in a 59-patient, four-week trial, is adequately supported.",
      "source": "Launch-HTN, JAMA 2025 (full text, Table 3): https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/; Mineralys 10-K filed 2026-03-12 (safety results of both pivotal trials and Explore-CKD): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm; Advance-HTN, N Engl J Med 2025: https://pubmed.ncbi.nlm.nih.gov/40267417/; NephJC commentary on Advance-HTN: http://www.nephjc.com/news/advance-htn-lorundrostat; Explore-CKD, Kidney Int 2026: https://pubmed.ncbi.nlm.nih.gov/42778148/; umbrella review, Am J Cardiovasc Drugs 2026;26:603-619: https://pubmed.ncbi.nlm.nih.gov/42489850/; Baxfendy prescribing information, sections 5 and 6.1: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf"
    },
    {
      "factor": "No advisory committee expected, and the company describes a routine review",
      "direction": "+",
      "step": "small",
      "evidence": "Mineralys's quarterly reports of 6 May and 11 August 2026 both describe an advisory committee meeting as \"not anticipated currently\"; none was held for baxdrostat. The company received pre-submission feedback from FDA in October 2025, submitted the application in December 2025, and was notified of its acceptance on 6 March 2026; the 12-month timetable is that of a standard review, and no priority review was announced. On 11 August 2026 the chief executive called the dialogue with FDA \"regular course\" with \"no surprises\" and expected discussions on labeling and post-approval commitments in October or November; on 9 September management said the dialogue continued to be productive. Limits: all of this is the company's own account. No FDA document on this review is public, the outcomes of the mid-cycle and late-cycle steps have not been disclosed, and the company has filed no 8-K since 11 August 2026.",
      "source": "Mineralys 10-Q filed 2026-05-06: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000084/mlys-20260331.htm; Mineralys 10-Q filed 2026-08-11: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm; Mineralys press release, 2025-11-10: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm; Mineralys 8-K, 2026-01-06: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys-20260106.htm; Mineralys 8-K, 2026-03-09: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm; Q2 2026 results call transcript, 2026-08-11: https://www.fool.com/earnings/call-transcripts/2026/08/18/mineralys-mlys-q2-2026-earnings-call-transcript/; Investing.com report of the Wells Fargo conference, 2026-09-09: https://in.investing.com/news/stock-market-news/mineralys-at-wells-fargo-conference-lorundrostat-launch-takes-shape-93CH-5587269; FDA approval letter for Baxfendy: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf; SEC EDGAR filing list for Mineralys (CIK 1933414), as of 2026-10-05"
    },
    {
      "factor": "Manufacturing cannot be checked, and this is the company's first product",
      "direction": "-",
      "step": "medium",
      "evidence": "Mineralys has never had a product approved and owns no manufacturing facilities; the active ingredient and the tablets are made entirely by contract manufacturers. None of them is named in the company's SEC filings, so their FDA inspection histories cannot be looked up. The annual report filed on 12 March 2026 says the company had no long-term supply agreements with any manufacturer, had not arranged redundant supply or a second source for all the raw materials it needs, and that the process used for current clinical material differs from the one used in earlier trials. The same report notes that FDA inspects the manufacturing facilities after an application is submitted. No inspection result, Form 483 or warning letter connected with lorundrostat is on public record, and the company has not commented on the manufacturing part of the review. On the other side, the product is a conventional once-daily tablet of a small molecule, a comparatively simple kind of product to make. This is the part of the application about which the least is publicly known.",
      "source": "Mineralys 10-K filed 2026-03-12 (Manufacturing; risk factors on third-party manufacturers): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm; Mineralys 10-Q filed 2026-08-11: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm; ClinicalTrials.gov NCT05968430 (tablet, administered orally): https://clinicaltrials.gov/study/NCT05968430"
    },
    {
      "factor": "The company is committing money and people on the assumption of approval",
      "direction": "+",
      "step": "small",
      "evidence": "In June 2026 Mineralys paid Tanabe $200.0 million upfront to end its royalty obligations on lorundrostat and arranged a loan facility of up to $500.0 million. It drew $100.0 million; a further $150.0 million is to be drawn by 30 April 2027 once FDA approves the application, and the whole loan must be repaid early if approval has not come by 30 September 2027. Cash and investments were $661.4 million on 30 June 2026. In August the company said its commercial leadership was in place, initial sales territories had been identified and the sales organization would be established before the goal date. A new chief medical officer started on 10 August 2026; his predecessor, who led development and the filing, stays on full-time as an adviser. Limits: this shows what management and its lenders expect, not what FDA thinks.",
      "source": "Mineralys 8-K, 2026-06-03 (license amendment and loan agreement): https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/mlys-20260602.htm; Mineralys 10-Q filed 2026-08-11: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm; Mineralys 8-K and press release, 2026-08-11: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys-20260805.htm and https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm"
    }
  ],
  "manufacturing_risk": {
    "level": "medium",
    "why": "Mineralys has no approved product and no manufacturing facilities of its own. The active ingredient and the tablets are made entirely by contract manufacturers that its SEC filings do not name, so their FDA inspection records cannot be checked, and no inspection outcome, Form 483 or warning letter linked to lorundrostat is on public record. The annual report of 12 March 2026 says the company had no long-term supply agreements, had not arranged a second source for all the raw materials it needs, and that the process for current clinical material differs from the one used in earlier trials. In its favour, the product is a conventional once-daily tablet of a small molecule, not a sterile or biological product. What cannot be judged: which sites are named in the application, whether FDA has inspected them and with what result, and whether the manufacturing section has drawn questions from FDA. The level is set at medium because of these unknowns, not because of any reported problem."
  },
  "what_would_change_my_mind": [
    "Up: Mineralys reports that discussions with FDA on labeling and post-approval commitments have begun (it expects them in October or November 2026), or that the manufacturing sites have been inspected without significant findings.",
    "Down: a Form 483 with significant observations, a warning letter or an adverse inspection classification at a maker of lorundrostat's active ingredient or tablets becomes public, or the company discloses manufacturing questions from FDA.",
    "Down: FDA schedules an advisory committee, or the company's next quarterly report (expected in November 2026) no longer calls one \"not anticipated\" or stops describing the review as routine.",
    "Down: the long-term Transform-HTN results on 8 November 2026 show a new safety problem, such as adrenal insufficiency or more severe hyperkalemia with longer treatment, or FDA tightens the safety labeling of Baxfendy.",
    "Little change on its own: FDA extends the goal date after a major amendment. The reason given for the extension would matter more than the delay.",
    "Void rather than no: Mineralys withdraws the application before FDA acts."
  ],
  "summary_en": "FDA approval of lorundrostat in this review cycle is put at 88%, above the 76% base rate for first-time applications from smaller companies. Both pivotal trials met their primary endpoints, lowering systolic pressure 9.1 and 7.9 mmHg more than placebo. In May 2026 FDA approved baxdrostat, the first drug of the same class, for an almost identical indication on blood-pressure data alone, without an advisory committee or special restrictions. Raised potassium, low sodium and reduced kidney function are known class effects that FDA has handled through labeling. The main unknown is manufacturing: this is the company's first product, its contract manufacturers are not named, and no inspection results are public. The FDA goal date is 22 December 2026.",
  "summary_zh": "FDA 在本轮审评中批准 lorundrostat 的概率估计为 88%，高于小公司首次申请 76% 的基准。两项关键试验均达到主要终点，收缩压比安慰剂分别多降 9.1 和 7.9 mmHg。2026 年 5 月，FDA 已批准同类首个药物 baxdrostat，适应症几乎相同，依据的只是降压数据，没有召开咨询委员会，也没有附加特殊限制。血钾升高、血钠降低和肾功能下降是这类药物已知的作用，FDA 此前是靠说明书来管理的。最大的未知数在生产：这是公司的第一个产品，合同生产商没有公开，也没有公开的检查结果。PDUFA 目标日期为 2026 年 12 月 22 日。",
  "sources": [
    "Mineralys 8-K, 2026-03-09 (FDA acceptance of the NDA, goal date, Explore-OSA topline): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm",
    "Mineralys press release, 2026-03-09 (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys202603068kex991.htm",
    "Mineralys 8-K, 2026-01-06 (NDA submitted in late 2025): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys-20260106.htm",
    "Mineralys 10-K for FY2025, filed 2026-03-12: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm",
    "Mineralys 10-Q for Q1 2026, filed 2026-05-06: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000084/mlys-20260331.htm",
    "Mineralys 10-Q for Q2 2026, filed 2026-08-11: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm",
    "Mineralys 8-K, 2026-08-11 (Q2 results, chief medical officer change): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys-20260805.htm",
    "Mineralys press release, 2026-08-11 (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm",
    "Mineralys 8-K, 2026-06-03 (Tanabe license amendment, term loan): https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/mlys-20260602.htm",
    "Mineralys press release, 2025-11-10 (pre-NDA feedback): https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm",
    "Mineralys press release, 2026-09-23 (Transform-HTN late-breaking presentation on 8 November 2026): https://ir.mineralystx.com/news-events/press-releases/detail/116/mineralys-therapeutics-transform-htn-open-label",
    "SEC EDGAR filing list for Mineralys Therapeutics (CIK 1933414), as of 2026-10-05: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1933414&type=8-K",
    "FDA approval letter for Baxfendy (baxdrostat), NDA 219878, signed 2026-05-15: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf",
    "Baxfendy (baxdrostat) prescribing information, revised 5/2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf",
    "FDA, Novel Drug Approvals for 2026 (Baxfendy, 5/15/2026): https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
    "HCPLive, 2025-12-02 (baxdrostat NDA accepted under priority review): https://www.hcplive.com/view/fda-accepts-priority-review-nda-of-baxdrostat-for-uncontrolled-hypertension",
    "Launch-HTN: Saxena M et al., JAMA 2025;334(5):409-418: https://pubmed.ncbi.nlm.nih.gov/40587141/",
    "Launch-HTN full text (PubMed Central): https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/",
    "Advance-HTN: Laffin LJ et al., N Engl J Med 2025;392(18):1813-1823: https://pubmed.ncbi.nlm.nih.gov/40267417/",
    "Target-HTN: Laffin LJ et al., JAMA 2023;330(12):1140-1150: https://pubmed.ncbi.nlm.nih.gov/37690061/",
    "Explore-CKD: Weir MR et al., Kidney Int 2026 (online 2026-09-23): https://pubmed.ncbi.nlm.nih.gov/42778148/",
    "Umbrella review of lorundrostat meta-analyses, Am J Cardiovasc Drugs 2026;26(5):603-619: https://pubmed.ncbi.nlm.nih.gov/42489850/",
    "NephJC commentary on Advance-HTN: http://www.nephjc.com/news/advance-htn-lorundrostat",
    "ClinicalTrials.gov NCT05968430 (Transform-HTN open-label extension): https://clinicaltrials.gov/study/NCT05968430",
    "Mineralys Q2 2026 results call transcript, 2026-08-11: https://www.fool.com/earnings/call-transcripts/2026/08/18/mineralys-mlys-q2-2026-earnings-call-transcript/",
    "Investing.com report of Mineralys at the Wells Fargo Healthcare Conference, 2026-09-09: https://in.investing.com/news/stock-market-news/mineralys-at-wells-fargo-conference-lorundrostat-launch-takes-shape-93CH-5587269"
  ],
  "zh": {
    "indication": "成人高血压，与其他降压药联合使用（未控制或难治性高血压）",
    "key_factors": [
      {
        "factor": "FDA 已于 2026 年 5 月批准同类首个药物，适应症几乎相同",
        "evidence": "2026 年 5 月 15 日，FDA 批准了 AstraZeneca 的 Baxfendy（baxdrostat），这是首个醛固酮合成酶抑制剂，适应症为与其他降压药联合治疗高血压，用于其他药物控制不佳的成人降低血压。lorundrostat 申报的适应症是与其他降压药联合治疗成人高血压。baxdrostat 的批准依据是一项 3 期试验（BaxHTN，794 名患者随机入组）的降压结果：第 12 周坐位收缩压比安慰剂多降 9.8 mmHg（2 mg）和 8.7 mmHg（1 mg），p 值均 <0.0001。说明书写明，没有对照试验证明该药本身能减少心血管事件。说明书没有黑框警告，也没有禁忌症；高钾血症和低钠血症列为警告，靠验血监测来管理。批准函写明，该申请没有提交咨询委员会，理由是它没有提出重大的公共卫生问题，也不存在有争议的事项；批准后要求开展的研究只涉及儿童、哺乳和妊娠。批准函由 FDA 心脏病学、血液学、内分泌学和肾脏病学办公室主任签署，高血压药物在该办公室的职责范围之内。这一先例的局限：baxdrostat 出自大公司，走的是优先审评；它的获批也说明不了 lorundrostat 的生产情况。"
      },
      {
        "factor": "两项关键试验均明确达到主要终点",
        "evidence": "Launch-HTN（3 期；1,083 名正在服用 2 至 5 种降压药的成人，13 个国家 159 个中心；JAMA 2025）：第 6 周自动诊室收缩压在 lorundrostat 50 mg 组下降 16.9 mmHg，安慰剂组下降 7.9 mmHg，相差 9.1 mmHg（95% CI 4.9 至 13.3；P<.001）。第 12 周，50 mg 组与安慰剂相差 11.6 mmHg（p<0.0001），可增量至 100 mg 的一组相差 8.4 mmHg（p=0.0016）。Advance-HTN（2 期，被定为关键试验；285 名在标准化方案下血压仍高的成人；NEJM 2025）：第 12 周 24 小时动态收缩压，50 mg 组比安慰剂多降 7.9 mmHg（97.5% CI 2.6 至 13.3），剂量调整组多降 6.5 mmHg（97.5% CI 1.2 至 11.8）。支持性试验方向一致：Target-HTN（200 名患者；50 mg 多降 9.6 mmHg，P=.01）和 Explore-CKD（59 名肾病患者；25 mg 多降 7.5 mmHg，p=0.0024）。Explore-OSA 未达主要终点，但那是一项睡眠呼吸暂停指标，不在本次申请之内；血压仍比安慰剂多降 6.2 mmHg。这些降幅与 baxdrostat 处于同一水平。100 mg 并不比 50 mg 更有效；公司表示申报的是 25 mg 和 50 mg 两个剂量。"
      },
      {
        "factor": "未见皮质醇受抑制，安全性数据库不小于首个获批药物说明书所载的规模",
        "evidence": "这类药物长期以来的顾虑是会同时抑制皮质醇合成。在 Launch-HTN 中，服用 lorundrostat 的受试者没有一例经刺激试验确认的糖皮质激素缺乏，Target-HTN 也没有报告皮质醇不足；Baxfendy 的说明书同样写明对刺激后的皮质醇没有影响。在 Launch-HTN 中，lorundrostat 组的严重不良事件（2.2% 和 0.7%）少于安慰剂组（3.0%），唯一的死亡病例出现在安慰剂组。两项关键试验共有 1,001 名患者被随机分到 lorundrostat 组（811 + 190），另有 1,076 名患者进入 Transform-HTN 扩展研究；该研究提供最长 52 周的开放标签治疗，含一个随机撤药阶段，并作为支持性材料纳入申请。作为对照，Baxfendy 的说明书描述的是 774 名用药患者的 12 周对照数据，以及 192 名和 172 名患者的长期数据。申请中有多少 lorundrostat 患者用药满一年或更久，尚未公布；长期结果定于 2026 年 11 月 8 日在 American Heart Association 年会上发布。"
      },
      {
        "factor": "对血钾、血钠和肾功能的影响，在风险较高的那项试验中更明显",
        "evidence": "与安慰剂相比，lorundrostat 更常引起血钾升高、血钠降低和肾功能指标下降。在 Launch-HTN 中，论文报告的特别关注不良事件为：高钾血症在 lorundrostat 两组为 2.0% 和 2.6%，安慰剂组 0.4%；低钠血症 6.9% 和 10.4%，安慰剂组 3.3%；肾功能下降 3.0% 和 3.3%，安慰剂组 0.7%；因其中任何一项而停药的不到 1%。血钾高于 6.0 mmol/L 的比例为 1.1% 和 1.5%（复测后为 0.6% 和 1.1%）。在 Advance-HTN 中，所有患者都在使用含利尿剂和血管紧张素受体拮抗剂的优化方案，lorundrostat 两组血钾高于 6.0 mmol/L 的比例为 5.3% 和 7.4%，安慰剂组无一例（复测后为 2.1% 和 3.2%）；严重不良事件也更多（6.4% 和 8.4%，安慰剂组 2.1%）；剂量调整组有 1 例死亡，被判定与药物无关。在 Explore-CKD 中，25 mg 治疗期 58 名患者中有 3 名（5%）出现经确认的高钾血症，安慰剂期无一例。已发表的对同一批试验的汇总分析给出的高钾血症相对风险在 3.19 至 11.63 之间。FDA 对 baxdrostat 的同类作用是用警告和监测来处理的，因此这些发现更可能影响说明书的写法，而不是挡住批准。尚不明朗的是：FDA 如何计算未经复测确认的血钾读数，以及主要只在一项 59 人、为期四周的试验中研究过的 25 mg 剂量证据是否充分。"
      },
      {
        "factor": "预计不召开咨询委员会，公司称审评进展如常",
        "evidence": "Mineralys 在 2026 年 5 月 6 日和 8 月 11 日的季度报告中都写明，目前预计不会召开咨询委员会；baxdrostat 当时也没有开。公司在 2025 年 10 月收到 FDA 的申报前反馈，2025 年 12 月提交申请，2026 年 3 月 6 日接到受理通知；12 个月的时间表对应标准审评，公司没有宣布获得优先审评。2026 年 8 月 11 日，首席执行官称与 FDA 的沟通属于常规进程、没有意外，并预计说明书和批准后承诺事项的讨论会在 10 月或 11 月进行；9 月 9 日管理层表示沟通仍然富有成效。局限：以上都是公司自己的说法。FDA 方面没有任何关于这次审评的公开文件，中期和后期审评节点的结果没有披露，公司自 2026 年 8 月 11 日以来也没有再提交 8-K。"
      },
      {
        "factor": "生产环节无从查证，而且这是公司的第一个产品",
        "evidence": "Mineralys 从未有产品获批，也没有自己的生产设施；原料药和片剂全部由合同生产商制造。公司向 SEC 提交的文件没有点名其中任何一家，因此无法查询它们的 FDA 检查记录。2026 年 3 月 12 日提交的年报写明，公司没有与任何生产商签订长期供货协议，尚未为所需的全部原材料安排备用供应或第二来源，而且目前临床用药所用的工艺与早期试验所用的不同。该年报还提到，FDA 会在申请提交之后检查生产设施。公开资料未见与 lorundrostat 有关的检查结果、Form 483 或警告信，公司也没有谈及审评中的生产部分。另一方面，产品是小分子药物的常规每日一次片剂，属于生产上相对简单的一类。这是整份申请中外界所知最少的部分。"
      },
      {
        "factor": "公司正按获批的预期投入资金和人员",
        "evidence": "2026 年 6 月，Mineralys 向 Tanabe 一次性支付 $200.0 million（2 亿美元），了结 lorundrostat 的特许权使用费义务，并安排了一笔最高 $500.0 million（5 亿美元）的贷款。公司已提取 $100.0 million（1 亿美元）；另有 $150.0 million（1.5 亿美元）须在 FDA 批准申请后、不迟于 2027 年 4 月 30 日提取；如果到 2027 年 9 月 30 日仍未获批，整笔贷款须提前偿还。截至 2026 年 6 月 30 日，现金和投资为 $661.4 million（6.614 亿美元）。公司 8 月表示，商业化管理团队已经到位，首批销售区域已经划定，销售队伍将在目标日期之前组建完成。新任首席医学官于 2026 年 8 月 10 日上任；主持研发和申报的前任留任全职顾问。局限：这反映的是管理层及其贷款方的预期，不代表 FDA 的看法。"
      }
    ],
    "manufacturing_risk_why": "Mineralys 没有已获批的产品，也没有自己的生产设施。原料药和片剂全部由合同生产商制造，公司向 SEC 提交的文件没有点名这些生产商，因此无法核对它们的 FDA 检查记录；公开资料也未见与 lorundrostat 有关的检查结论、Form 483 或警告信。2026 年 3 月 12 日的年报写明，公司没有长期供货协议，尚未为所需的全部原材料安排第二来源，而且目前临床用药的工艺与早期试验所用的不同。有利的一面是，产品是小分子药物的常规每日一次片剂，不是无菌制剂或生物制品。无法判断的部分：申请中列出了哪些生产场地，FDA 是否已经检查、结果如何，以及生产部分是否引来 FDA 的问询。风险定为中等，是因为这些未知数，而不是因为出现了任何已报告的问题。",
    "what_would_change_my_mind": [
      "上调：Mineralys 披露已与 FDA 就说明书和批准后承诺事项展开讨论（公司预计在 2026 年 10 月或 11 月进行），或披露生产场地已接受检查且没有重大发现。",
      "下调：lorundrostat 原料药或片剂生产商被公开开出含重大观察项的 Form 483、收到警告信或得到不利的检查定性，或公司披露 FDA 就生产提出了问题。",
      "下调：FDA 安排召开咨询委员会，或公司下一份季度报告（预计 2026 年 11 月）不再写明预计不会召开，或不再把审评描述为进展如常。",
      "下调：2026 年 11 月 8 日公布的 Transform-HTN 长期结果显示新的安全性问题，例如肾上腺皮质功能不全，或随用药时间延长出现更严重的高钾血症；或 FDA 收紧 Baxfendy 的安全性说明。",
      "单看影响不大：FDA 因重大补充而延后目标日期。延期的理由比延期本身更重要。",
      "作废而非判否：Mineralys 在 FDA 作出决定前撤回申请。"
    ]
  },
  "recorded_at": "2026-10-05T08:21:33+00:00"
}